Cargando…
Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors
To date there are no therapies for patients with congenital myopathies, muscle disorders causing poor quality of life of affected individuals. In approximately 30% of the cases, patients with congenital myopathies carry either dominant or recessive mutations in the ryanodine receptor 1 (RYR1) gene;...
Autores principales: | Ruiz, Alexis, Benucci, Sofia, Duthaler, Urs, Bachmann, Christoph, Franchini, Martina, Noreen, Faiza, Pietrangelo, Laura, Protasi, Feliciano, Treves, Susan, Zorzato, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956288/ https://www.ncbi.nlm.nih.gov/pubmed/35238775 http://dx.doi.org/10.7554/eLife.73718 |
Ejemplares similares
-
Targeted transcript analysis in muscles from patients with genetically diverse congenital myopathies
por: Bachmann, Christoph, et al.
Publicado: (2022) -
Quantitative proteomic analysis of skeletal muscles from wild-type and transgenic mice carrying recessive Ryr1 mutations linked to congenital myopathies
por: Eckhardt, Jan, et al.
Publicado: (2023) -
I-13
Muscle ryanodine receptor in congenital
myopathies and channelopathies
por: Treves, S., et al.
Publicado: (2011) -
Calcium entry units (CEUs): perspectives in skeletal muscle function and disease
por: Protasi, Feliciano, et al.
Publicado: (2020) -
Improper Remodeling of Organelles Deputed to Ca(2+) Handling and Aerobic ATP Production Underlies Muscle Dysfunction in Ageing
por: Protasi, Feliciano, et al.
Publicado: (2021)